279 related articles for article (PubMed ID: 11821958)
21. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer.
Tang CK; Gong XQ; Moscatello DK; Wong AJ; Lippman ME
Cancer Res; 2000 Jun; 60(11):3081-7. PubMed ID: 10850460
[TBL] [Abstract][Full Text] [Related]
22. Analysis of IL-6-mediated growth control of myeloma cells using a gp130 chimeric receptor approach.
French JD; Tschumper RC; Jelinek DF
Leukemia; 2002 Jun; 16(6):1189-96. PubMed ID: 12040452
[TBL] [Abstract][Full Text] [Related]
23. MEK/ERK and signal transducer and activator of transcription signaling pathways modulate oncostatin M-stimulated CCL2 expression in human osteoblasts through a common transcription factor.
Lin SK; Kok SH; Yeh FT; Kuo MY; Lin CC; Wang CC; Goldring SR; Hong CY
Arthritis Rheum; 2004 Mar; 50(3):785-93. PubMed ID: 15022320
[TBL] [Abstract][Full Text] [Related]
24. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors.
Creighton CJ; Hilger AM; Murthy S; Rae JM; Chinnaiyan AM; El-Ashry D
Cancer Res; 2006 Apr; 66(7):3903-11. PubMed ID: 16585219
[TBL] [Abstract][Full Text] [Related]
25. Epidermal growth factor induces insulin receptor substrate-2 in breast cancer cells via c-Jun NH(2)-terminal kinase/activator protein-1 signaling to regulate cell migration.
Cui X; Kim HJ; Kuiatse I; Kim H; Brown PH; Lee AV
Cancer Res; 2006 May; 66(10):5304-13. PubMed ID: 16707456
[TBL] [Abstract][Full Text] [Related]
26. Oncostatin M suppresses EGF-mediated protein tyrosine phosphorylation in breast cancer cells.
Spence MJ; Vestal RE; Ma Y; Streiff R; Liu J
Cytokine; 2000 Jul; 12(7):922-33. PubMed ID: 10880237
[TBL] [Abstract][Full Text] [Related]
27. Activation of the Jak-Stat- and MAPK-pathways by oncostatin M is not sufficient to cause growth inhibition of human glioma cells.
Halfter H; Postert C; Friedrich M; Ringelstein EB; Stögbauer F
Brain Res Mol Brain Res; 2000 Sep; 80(2):198-206. PubMed ID: 11038252
[TBL] [Abstract][Full Text] [Related]
28. Cell density-dependent regulation of hepatic development by a gp130-independent pathway.
Kojima N; Kinoshita T; Kamiya A; Nakamura K; Nakashima K; Taga T; Miyajima A
Biochem Biophys Res Commun; 2000 Oct; 277(1):152-8. PubMed ID: 11027656
[TBL] [Abstract][Full Text] [Related]
29. Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.
Pedersen NM; Breen K; Rødland MS; Haslekås C; Stang E; Madshus IH
Mol Cancer Res; 2009 Feb; 7(2):275-84. PubMed ID: 19208749
[TBL] [Abstract][Full Text] [Related]
30. Y-box-binding protein 1 confers EGF independence to human mammary epithelial cells.
Berquin IM; Pang B; Dziubinski ML; Scott LM; Chen YQ; Nolan GP; Ethier SP
Oncogene; 2005 Apr; 24(19):3177-86. PubMed ID: 15735691
[TBL] [Abstract][Full Text] [Related]
31. Grb2 regulates Stat3 activation negatively in epidermal growth factor signalling.
Zhang T; Ma J; Cao X
Biochem J; 2003 Dec; 376(Pt 2):457-64. PubMed ID: 14498832
[TBL] [Abstract][Full Text] [Related]
32. Unique role of SNT-2/FRS2beta/FRS3 docking/adaptor protein for negative regulation in EGF receptor tyrosine kinase signaling pathways.
Huang L; Watanabe M; Chikamori M; Kido Y; Yamamoto T; Shibuya M; Gotoh N; Tsuchida N
Oncogene; 2006 Oct; 25(49):6457-66. PubMed ID: 16702953
[TBL] [Abstract][Full Text] [Related]
33. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
34. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells.
Song L; Turkson J; Karras JG; Jove R; Haura EB
Oncogene; 2003 Jul; 22(27):4150-65. PubMed ID: 12833138
[TBL] [Abstract][Full Text] [Related]
35. Oncostatin M, an interleukin-6 family cytokine, upregulates matrix metalloproteinase-9 through the mitogen-activated protein kinase kinase-extracellular signal-regulated kinase pathway in cultured smooth muscle cells.
Nagata T; Kai H; Shibata R; Koga M; Yoshimura A; Imaizumi T
Arterioscler Thromb Vasc Biol; 2003 Apr; 23(4):588-93. PubMed ID: 12615664
[TBL] [Abstract][Full Text] [Related]
36. Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells.
Tari AM; Hung MC; Li K; Lopez-Berestein G
Oncogene; 1999 Feb; 18(6):1325-32. PubMed ID: 10022814
[TBL] [Abstract][Full Text] [Related]
37. Protein kinase A-Ialpha subunit-directed antisense inhibition of ovarian cancer cell growth: crosstalk with tyrosine kinase signaling pathway.
Alper O; Hacker NF; Cho-Chung YS
Oncogene; 1999 Sep; 18(35):4999-5004. PubMed ID: 10490835
[TBL] [Abstract][Full Text] [Related]
38. Blocking HER-2/HER-3 function with a dominant negative form of HER-3 in cells stimulated by heregulin and in breast cancer cells with HER-2 gene amplification.
Ram TG; Schelling ME; Hosick HL
Cell Growth Differ; 2000 Mar; 11(3):173-83. PubMed ID: 10768865
[TBL] [Abstract][Full Text] [Related]
39. Differential expression and effects of gp130 cytokines and receptors in prostate cancer cells.
Palmer J; Hertzog PJ; Hammacher A
Int J Biochem Cell Biol; 2004 Nov; 36(11):2258-69. PubMed ID: 15313471
[TBL] [Abstract][Full Text] [Related]
40. Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.
Maegawa M; Takeuchi K; Funakoshi E; Kawasaki K; Nishio K; Shimizu N; Ito F
Mol Cancer Res; 2007 Apr; 5(4):393-401. PubMed ID: 17426253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
